Event – Sydney: What is the meaning of Myriad?
Prior to the High Court of Australia decision in D’Arcy v Myriad Genetics Inc., handed down on 7 October 2015, the law in Australia governing what types of technologies could be patent protected was relatively clear.
In the wake of the Myriad decision, all of this could change. Although the decision relates directly to human genes, the impact of the decision has the potential to affect patent protection on gene technologies more generally, as well as naturally occurring chemicals, ICT inventions and other new technologies.
DCC and AusBiotech welcome you to learn about the background and impact of the decision and IP Australia’s interpretation of it. The practical effects of the decision will be discussed by our expert panel with delegate interaction.
The full seminar video is below, and includes quick link chapter markers allowing you to skip to each presentation.
|WHERE||Davies Collison Cave
Level 14, 255 Elizabeth Street
Sydney NSW 2000
|WHEN||Thursday 26th November 2015
3.30pm – 5.00pm
Refreshments on arrival
|RSVP||Friday 20th November by email to email@example.com|